Scholarlink

Purpose <p>Colorectal cancer (CRC) is a major cause of cancer-related mortality. Current prognostic models rely primarily on tumor-specific features and may overlook host-tumor interactions. We conducted this study to assess the prognostic value of the cancer-inflammation prognostic index (CIPI), which combines carcinoembryonic antigen and neutrophil-to-lymphocyte ratio, in patients with stage II CRC.</p> Methods <p>The subjects of this retrospective study were 326 patients with pathologically confirmed stage II CRC who underwent curative resection at our hospital between 2008 and 2018. The optimal CIPI cutoff for predicting 5&#xa0;year survival was established using receiver operating characteristic analysis. Patients were classified into High- and Low-CIPI groups, and survival outcomes were compared.</p> Results <p>Multivariate analysis identified a high CIPI (≥ 56.9) and inadequate lymph node dissection (≤ 12 nodes) as independent predictors of worse disease-free survival (DFS), and a high CIPI, older age, performance status ≥ 3, and limited lymph node dissection as independent predictors of worse overall survival (OS). Patients with a high-CIPI had significantly lower 5&#xa0;year DFS and OS.</p> Conclusion <p>CIPI is a simple, objective preoperative biomarker independently associated with recurrence and survival in patients with stage II CRC and may enhance risk stratification for adjuvant therapy and postoperative surveillance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical utility of the cancer-inflammation prognostic index for identifying high-risk stage II colorectal cancer

  • 期刊论文

  • 发表日期：

    2025年10月8日

查看全文
  • Masahisa Ohkuma,
  • Teppei Kamada,
  • Keisuke Goto,
  • Shu Tsukihara,
  • Yasunobu Kobayashi,
  • Tadashi Abe,
  • Yasuhiro Takano,
  • Yuta Imaizumi,
  • Shunjin Ryu,
  • Yasuhiro Takeda,
  • Makoto Kosuge,
  • Ken Eto

摘要

Purpose

Colorectal cancer (CRC) is a major cause of cancer-related mortality. Current prognostic models rely primarily on tumor-specific features and may overlook host-tumor interactions. We conducted this study to assess the prognostic value of the cancer-inflammation prognostic index (CIPI), which combines carcinoembryonic antigen and neutrophil-to-lymphocyte ratio, in patients with stage II CRC.

Methods

The subjects of this retrospective study were 326 patients with pathologically confirmed stage II CRC who underwent curative resection at our hospital between 2008 and 2018. The optimal CIPI cutoff for predicting 5 year survival was established using receiver operating characteristic analysis. Patients were classified into High- and Low-CIPI groups, and survival outcomes were compared.

Results

Multivariate analysis identified a high CIPI (≥ 56.9) and inadequate lymph node dissection (≤ 12 nodes) as independent predictors of worse disease-free survival (DFS), and a high CIPI, older age, performance status ≥ 3, and limited lymph node dissection as independent predictors of worse overall survival (OS). Patients with a high-CIPI had significantly lower 5 year DFS and OS.

Conclusion

CIPI is a simple, objective preoperative biomarker independently associated with recurrence and survival in patients with stage II CRC and may enhance risk stratification for adjuvant therapy and postoperative surveillance.